Potential for Nuclear Medicine Therapy for Glioblastoma Treatment.
cancer
glioblastoma
nuclear medicine
peptide receptor radiotherapy (PRRT)
radioimmunotherapy (RIT)
radionanoparticles
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
01
2019
accepted:
14
06
2019
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
30
7
2019
Statut:
epublish
Résumé
Glioblastoma is the most common malignant adult brain tumor and has a very poor patient prognosis. The mean survival for highly proliferative glioblastoma is only 10 to 14 months despite an aggressive current therapeutic approach known as Stupp's protocol, which consists of debulking surgery followed by radiotherapy and chemotherapy. Despite several clinical trials using anti-angiogenic targeted therapies, glioblastoma medical care remains without major progress in the last decade. Recent progress in nuclear medicine, has been mainly driven by advances in biotechnologies such as radioimmunotherapy, radiopeptide therapy, and radionanoparticles, and these bring a new promising arsenal for glioblastoma therapy. For therapeutic purposes, nuclear medicine practitioners classically use β
Identifiants
pubmed: 31354487
doi: 10.3389/fphar.2019.00772
pmc: PMC6637301
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
772Références
J Nucl Med. 1999 Apr;40(4):631-8
pubmed: 10210222
Acta Oncol. 1999;38(3):351-9
pubmed: 10380827
Cancer Res. 2000 Mar 1;60(5):1383-7
pubmed: 10728703
J Clin Oncol. 2000 Nov 15;18(22):3862-72
pubmed: 11078500
J Clin Oncol. 2002 Mar 1;20(5):1389-97
pubmed: 11870184
Semin Nucl Med. 2002 Apr;32(2):148-55
pubmed: 11965610
Am J Clin Oncol. 2002 Dec;25(6):541-6
pubmed: 12477994
Int J Cancer. 1992 Apr 22;51(1):7-13
pubmed: 1373410
Q J Nucl Med Mol Imaging. 2004 Sep;48(3):220-8
pubmed: 15499296
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neurosurgery. 2005 Jun;56(6):1243-52; discussion 1252-3
pubmed: 15918940
J Nucl Med. 2005 Jun;46(6):1042-51
pubmed: 15937318
J Neurooncol. 2005 Nov;75(2):215-20
pubmed: 16283445
J Clin Oncol. 2006 Jan 1;24(1):115-22
pubmed: 16382120
Expert Opin Biol Ther. 2006 May;6(5):539-45
pubmed: 16610983
J Nucl Med. 2006 Jun;47(6):912-8
pubmed: 16741299
Clin Cancer Res. 2006 Jun 15;12(12):3843-50
pubmed: 16778112
J Clin Oncol. 2006 Aug 1;24(22):3644-50
pubmed: 16877732
Neurosurgery. 2007 Sep;61(3):570-8; discussion 578-9
pubmed: 17881971
J Nucl Med. 2008 Jan;49(1):30-8
pubmed: 18077533
Cancer Biol Ther. 2008 Mar;7(3):333-9
pubmed: 18094616
Neuro Oncol. 2008 Apr;10(2):182-9
pubmed: 18287339
J Nucl Med. 2010 Mar;51(3):397-400
pubmed: 20150267
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1335-44
pubmed: 20157707
J Neurooncol. 2010 Oct;100(1):129-36
pubmed: 20217458
J Neurosurg. 2010 Aug;113(2):192-8
pubmed: 20345222
Theranostics. 2011 Mar 01;1:201-10
pubmed: 21547160
Biomaterials. 2011 Oct;32(28):6781-90
pubmed: 21705077
Radiology. 2011 Oct;261(1):136-43
pubmed: 21813738
Neuro Oncol. 2012 Apr;14(4):416-25
pubmed: 22427110
Future Oncol. 2012 Jun;8(6):659-69
pubmed: 22764763
Anticancer Res. 2014 Apr;34(4):1885-91
pubmed: 24692723
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
Neuro Oncol. 2015 Mar;17 Suppl 2:ii3-ii8
pubmed: 25746090
Oncotarget. 2015 May 10;6(13):11664-75
pubmed: 25860928
Future Oncol. 2015;11(10):1531-41
pubmed: 25963430
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
CNS Oncol. 2015;4(4):225-34
pubmed: 26103989
J Neurosurg. 2015 Sep;123(3):760-70
pubmed: 26140493
Cancer Immunol Res. 2016 Feb;4(2):124-35
pubmed: 26546453
Theranostics. 2016 Jan 25;6(3):428-34
pubmed: 26909116
Semin Nucl Med. 2016 May;46(3):243-9
pubmed: 27067505
J Nucl Med. 2016 Oct;57(10):1576-1582
pubmed: 27127217
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Nucl Med. 2016 Nov;57(11):1771-1777
pubmed: 27261519
J Clin Neurosci. 2016 Nov;33:52-58
pubmed: 27452128
J Cell Sci. 2016 Dec 1;129(23):4321-4327
pubmed: 27875272
Asian Pac J Cancer Prev. ;18(1):3-9
pubmed: 28239999
Curr Neurol Neurosci Rep. 2017 Feb;17(2):19
pubmed: 28271343
Neurotherapeutics. 2017 Apr;14(2):284-297
pubmed: 28281173
Neuro Oncol. 2017 May 1;19(5):614-624
pubmed: 28339700
Front Pharmacol. 2017 May 09;8:242
pubmed: 28536525
Nucl Med Biol. 2017 Oct;53:1-8
pubmed: 28683361
Methods. 2017 Nov 1;130:63-71
pubmed: 28916148
Theranostics. 2017 Oct 12;7(18):4517-4536
pubmed: 29158842
Nucl Med Biol. 2018 May;60:55-62
pubmed: 29571067
Chem Biol Drug Des. 2018 Jul;92(1):1344-1356
pubmed: 29611298
Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1636-1644
pubmed: 29713762
Neuropathology. 2018 Oct;38(5):457-462
pubmed: 29952031
Cancer Med. 2018 Oct;7(10):5281-5290
pubmed: 30175510
Top Anticancer Res. 2015;5:3-42
pubmed: 30272043
J Clin Oncol. 2018 Oct 23;:JCO2018789990
pubmed: 30351999
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):614-622
pubmed: 30498897
Cell Biophys. 1994;24-25:37-43
pubmed: 7537631
Int J Cancer. 1995 Jun 9;61(6):786-92
pubmed: 7790112
Am J Physiol. 1993 Feb;264(2 Pt 1):C361-9
pubmed: 8383429
J Neurooncol. 1995;24(1):109-22
pubmed: 8523067
Cancer Res. 1996 Jan 1;56(1):182-9
pubmed: 8548761